{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(12)"],"submitter":["Goosen TC"],"pubmed_abstract":["Isavuconazole is a broad-spectrum triazole approved for the treatment of invasive aspergillosis or mucormycosis in adults and children aged ≥ 1 year. Current prescribing information lacks guidance regarding the co-administration of isavuconazole with anticancer drugs-limited by the availability of clinical drug-drug interaction (DDI) data in the patient population. This study utilized physiologically-based pharmacokinetic (PBPK) modeling to evaluate the DDI risk of isavuconazole compared with other azoles and provide dosing recommendations when co-administered with anticancer drugs (ibrutinib, venetoclax, and midostaurin). PBPK models were developed in the Simcyp simulator using physiochemical properties, in vitro, and clinical pharmacokinetic data. The model well-predicted isavuconazole p"],"journal":["CPT: pharmacometrics & systems pharmacology"],"pagination":["2198-2209"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12706401"],"repository":["biostudies-literature"],"pubmed_title":["Comparative Analysis of Isavuconazole DDIs With Other Azole Antifungal Drugs and PBPK Model-Informed Dosing Recommendations for Anticancer Drugs."],"pmcid":["PMC12706401"],"pubmed_authors":["Raber SR","Cheruvu N","Varma MVS","Goosen TC","Lin J","de Figueiredo MLN","Wu X"],"additional_accession":[]},"is_claimable":false,"name":"Comparative Analysis of Isavuconazole DDIs With Other Azole Antifungal Drugs and PBPK Model-Informed Dosing Recommendations for Anticancer Drugs.","description":"Isavuconazole is a broad-spectrum triazole approved for the treatment of invasive aspergillosis or mucormycosis in adults and children aged ≥ 1 year. Current prescribing information lacks guidance regarding the co-administration of isavuconazole with anticancer drugs-limited by the availability of clinical drug-drug interaction (DDI) data in the patient population. This study utilized physiologically-based pharmacokinetic (PBPK) modeling to evaluate the DDI risk of isavuconazole compared with other azoles and provide dosing recommendations when co-administered with anticancer drugs (ibrutinib, venetoclax, and midostaurin). PBPK models were developed in the Simcyp simulator using physiochemical properties, in vitro, and clinical pharmacokinetic data. The model well-predicted isavuconazole p","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-07T05:04:54.254Z","creation":"2026-06-07T03:06:55.281Z"},"accession":"S-EPMC12706401","cross_references":{"pubmed":["41104611"],"doi":["10.1002/psp4.70123"]}}